Cargando…

Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case

Currently, imatinib and dasatinib are the only tyrosine-kinase inhibitors approved in the US and Europe for the treatment of blast crisis of chronic myeloid leukemia (BC-CML) at diagnosis, while ponatinib is the only inhibitor used in patients bearing T315I mutation. Here we report the case of a 61-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bucelli, Cristina, Cattaneo, Daniele, Ferla, Valeria, Zappa, Manuela, de Benedittis, Caterina, Soverini, Simona, Iurlo, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584354/ https://www.ncbi.nlm.nih.gov/pubmed/28890835 http://dx.doi.org/10.1155/2017/6167345

Ejemplares similares

Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis
por: Küçükyurt, Selin, et al.
Publicado: (2023)

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
por: Pasquale, Raffaella, et al.
Publicado: (2022)

Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase
por: Lee, Jae Wook, et al.
Publicado: (2021)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
por: Iurlo, Alessandra, et al.
Publicado: (2021)

Pediatric chronic myeloid leukemia in myeloid blast crisis
por: Dey, Biswajit, et al.
Publicado: (2023)

BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
por: Parry, Narissa, et al.
Publicado: (2022)

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
por: Soverini, Simona, et al.
Publicado: (2016)

S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
por: Čuřík, Nikola, et al.
Publicado: (2023)

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia
por: Mancini, Manuela, et al.
Publicado: (2015)

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
por: Iurlo, Alessandra, et al.
Publicado: (2019)

New Perspectives on Polycythemia Vera: From Diagnosis to Therapy
por: Iurlo, Alessandra, et al.
Publicado: (2020)

Blast Crisis
por: Kirwin, Margaret, et al.
Publicado: (2020)

An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review
por: Orofino, Nicola, et al.
Publicado: (2017)

Molecular evidence for the clonal origin of blast crisis in chronic myeloid leukaemia.
por: Zalcberg, J. R., et al.
Publicado: (1986)

Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis
por: Godoy, C.R.T., et al.
Publicado: (2015)

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
por: Price, Kimberly E, et al.
Publicado: (2013)

A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
por: Korfi, K., et al.
Publicado: (2015)

Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
por: Musumeci, Francesca, et al.
Publicado: (2018)

P1018: TREND OF CIRCULATING CD34+ CELLS IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
por: Cattaneo, D., et al.
Publicado: (2022)

The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment
por: Hayashi, Kunio, et al.
Publicado: (2021)

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
por: Cattaneo, Daniele, et al.
Publicado: (2021)

Pediatric chronic myeloid leukemia with B-cell lymphoid blast crisis at presentation
por: Iyer, Prasad, et al.
Publicado: (2013)

Sudden Blast Crisis After Excellent Initial Response in Chronic Myeloid Leukemia
por: Vijaya Prakash, Aviraag, et al.
Publicado: (2021)

Bilateral Serous Retinal Detachment in Lymphoid Blast Crisis of Chronic Myeloid Leukemia
por: Umemura, Kyohei, et al.
Publicado: (2021)

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission
por: Dulucq, Stephanie, et al.
Publicado: (2022)

Acquired Factor VII Deficiency Associated With Chronic Myeloid Leukemia Blast Crisis
por: Wolf, Emily B., et al.
Publicado: (2023)

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities
por: Ren, Mingqiang, et al.
Publicado: (2012)

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
por: Molica, Matteo, et al.
Publicado: (2019)

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
por: Iurlo, Alessandra, et al.
Publicado: (2015)

Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality
por: Fattizzo, Bruno, et al.
Publicado: (2020)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022)

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
por: Caocci, Giovanni, et al.
Publicado: (2019)

Myodesopsia is a symptom of central nervous system blast crisis in chronic myeloid leukemia
por: Ishii, Kazuyoshi, et al.
Publicado: (2019)

Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia
por: Huang, Weiqi, et al.
Publicado: (2020)

Blast crisis of chronic myeloid leukemia initially presenting as severe acute intracerebral hemorrhage
por: Sharma, Shri Ram, et al.
Publicado: (2020)

Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients
por: Wang, Lulu, et al.
Publicado: (2021)

Megakaryocytic blast crisis in chronic myeloid leukiemia: An uncommon presentation in a common neoplasm
por: Agrawal, Shruti, et al.
Publicado: (2022)

Ponatinib‐induced ichthyosiform eruption
por: Kluger, Nicolas, et al.
Publicado: (2021)

Trend of circulating CD34(+) cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment
por: Iurlo, Alessandra, et al.
Publicado: (2022)

Myeloid Blast Crisis of Chronic Myeloid Leukemia Followed by Lineage Switch to B-Lymphoblastic Leukemia: A Case Report
por: Liu, Jiduo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_klpj8gf2scmipu5a8brsd69tai